Collaborative webinar: economic modelling in rare diseases

Mar 2, 2021

Watch the recording

 

It can be challenging to develop an economic model in rare diseases that optimises HTA and reimbursement outcomes. It can be difficult to fully capture the effects of the disease and the benefits of treatment whilst using sufficiently robust data to minimise uncertainty.

This webinar introduces a new approach in which multiple companies collaborate to develop a core economic model and common data set. An approach that aims to optimise HTA and reimbursement outcomes for all new treatments in a rare disease.

Speakers: Prof. Keith Abrams, Prof. John Brazier, Dr. Jill CarltonJosie GodfreyJamie O’Hara, Dr Mark Larkin, PhD, and Juliet Mumby-Croft

JG ZEBRA CONSULTING LTDHCD Economics LtdUniversity of LeicesterUniversity of YorkThe University of SheffieldVitaccessSource Health Economics.

#ProjectHERCULES #rarediseases #heor #healtheconomics #evidencebasedmedicine #pharmaceuticalindustry

More Insights

NICE RWE framework 

NICE RWE framework 

Previously, we discussed the use of real-world evidence (RWE) in the reimbursement assessment of medical devices. In this latest blog, we present an overview of the RWE framework created by the National Institute for Health and Care Excellence ... Read more

The 100,000 genomes project: paving the way for faster diagnosis and treatment of rare diseases

The 100,000 genomes project: paving the way for faster diagnosis and treatment of rare diseases

What are rare diseases?  In the  European Union, a rare disease is defined as a disorder affecting ≤5 in 10,000 persons  (1). Using this definition, the global population prevalence of rare diseases is estimated to be between 3.5–‍5.9% ... Read more

Use of RWE in the reimbursement assessment of medical devices

Use of RWE in the reimbursement assessment of medical devices

Hierarchy of evidence  Different study designs are often ranked in a hierarchy of evidence based on their validity and robustness. Randomised controlled trials (RCTs) are typically considered the gold standard source of evidence, ... Read more

The growing number of small interfering RNA-based therapies approved for reimbursement in the UK

The growing number of small interfering RNA-based therapies approved for reimbursement in the UK

The RNA interference pathway  Ribonucleic acid (RNA) is an important macromolecule in cells, involved in turning genetic information encoded by genes (made up of deoxyribonucleic acid ), into proteins needed by the cell. During the processes of ... Read more